02/08/2026 07:39
|
Medical, Health & Aged Care
Key Facts: IDH-mutant glioma is the most common malignant primary brain tumour in adults under 50 years of age.
VORANIGO® (vorasidenib) is now listed on the Pharmaceutical Benefits Scheme (PBS)...